Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Welt A, et al. Among authors: chiabudini m. Cancer Med. 2020 Jul;9(13):4527-4539. doi: 10.1002/cam4.3092. Epub 2020 Apr 30. Cancer Med. 2020. PMID: 32352244 Free PMC article. Clinical Trial.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: chiabudini m. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M, Fischer von Weikersthal L, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. Dechow T, et al. Among authors: chiabudini m. Cancer Med. 2021 Nov;10(22):8127-8137. doi: 10.1002/cam4.4310. Epub 2021 Oct 20. Cancer Med. 2021. PMID: 34668662 Free PMC article.
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M; TPK-Group (Tumour Registry Pancreatic Cancer). Marschner N, et al. Among authors: chiabudini m. Int J Cancer. 2023 Feb 1;152(3):458-469. doi: 10.1002/ijc.34271. Epub 2022 Sep 22. Int J Cancer. 2023. PMID: 36053905 Free PMC article.
Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score.
Wengenmayer T, Duerschmied D, Graf E, Chiabudini M, Benk C, Mühlschlegel S, Philipp A, Lubnow M, Bode C, Staudacher DL. Wengenmayer T, et al. Among authors: chiabudini m. Eur Heart J Acute Cardiovasc Care. 2019 Jun;8(4):350-359. doi: 10.1177/2048872618789052. Epub 2018 Jul 13. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 30003795
The ribosome-bound Hsp70 homolog Ssb of Saccharomyces cerevisiae.
Peisker K, Chiabudini M, Rospert S. Peisker K, et al. Among authors: chiabudini m. Biochim Biophys Acta. 2010 Jun;1803(6):662-72. doi: 10.1016/j.bbamcr.2010.03.005. Epub 2010 Mar 11. Biochim Biophys Acta. 2010. PMID: 20226819 Free article. Review.
17 results